Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11475-11484
DOI: 10.1111/dom.71299 ↗Abstract
ABSTRACT Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly used for obesity treatment, but real‐world adherence patterns, particularly among individuals without diabetes and paediatric patients, remain poorly characterised. We aimed to identify 12‐month GLP‐1 RA adherence trajectories among adults and paediatric patients with obesity without diabetes and to evaluate factors associated with adherence. Materials and Methods We conducted a retrospective cohort study using 2021–2023 MarketScan commercial claims data. Individuals aged ≥ 10 years with obesity without diabetes who initiated GLP‐1 RAs were included. Adherence was measured as monthly proportion of days covered (PDC) over 12 months. Group‐based trajectory modelling was conducted separately in adult and paediatric cohorts. Multivariable logistic regression was used to identify factors associated with membership in the persistent‐user trajectory. Results The study included 201 229 adults and 1139 paediatric patients. Five adherence trajectories were identified in each cohort. Among adults, trajectories included immediate discontinuers (19.6%), early discontinuers (23.5%), late discontinuers (20.7%), intermittent adherents (5.5%) and persistent users (30.7%), with mean annual PDC ranging from 0.10 to 0.87. Paediatric trajectory groups were more evenly distributed, with each group representing approximately 18%–22% of the cohort and persistent users comprising 20.3%. Geographic region was consistently associated with adherence, with higher odds of persistent use in the Northeast versus the South among adults (odds ratio [OR], 1.32) and paediatric patients (OR, 1.65). Conclusions Most adults and paediatric patients with obesity had suboptimal adherence to GLP‐1 RA use over 12 months. Distinct adherence trajectories and consistent regional differences highlight opportunities to better understand and address barriers to long‐term obesity pharmacotherapy.
EUVIMED